Identification of a PANoptosis-related prognostic model in triple-negative breast cancer, from risk assessment, immunotherapy, to personalized treatment
Important: Your dosage, treatment duration, and eligibility are determined individually by your provider based on your health history, wellness goals, and medical evaluation
Improves elasticity and youthful glow
The subsequent Phase IIb OPTIONS trial enrolled 536 subjects over 24 weeks
S., Armutcu, F., Sahin, S
The resistance to endocrine treatments including tamoxifen, aromatase inhibitors, and selective ER degraders is protected by dysregulation of these pathways, which in turn fuel hormone-dependent tumour growth (187, 188)